Welcome to our dedicated page for Lifestance Health Group news (Ticker: LFST), a resource for investors and traders seeking the latest updates and insights on Lifestance Health Group stock.
LifeStance Health Group, Inc. (LFST) provides investors and industry observers with timely access to corporate developments through this centralized news hub. Track official press releases, regulatory filings, and strategic announcements from one of the nation's leading outpatient mental healthcare providers.
Key resources include: Earnings reports detailing financial performance, partnership announcements with healthcare networks, expansions of clinical services, and leadership updates. This curated collection serves as a primary source for understanding LFST's operational milestones and market positioning.
All content reflects the company's focus on evidence-based behavioral healthcare and its commitment to expanding access through innovative care models. Regular updates ensure stakeholders stay informed about developments in teletherapy advancements, clinical research collaborations, and regulatory compliance matters.
Bookmark this page for direct access to LFST's verified corporate communications, eliminating the need to search multiple sources. Check back frequently for updates on operational metrics, facility expansions, and other material events shaping the company's trajectory in mental healthcare.
LifeStance Health Group, Inc. (Nasdaq: LFST) reported Q4 2022 revenue of $229.4 million, a 21% increase from the prior year, and a full-year revenue of $859.5 million, up 29%. The clinician base grew by 18% to 5,631. Despite the growth, the company recorded a net loss of $46.7 million for Q4 and $215.6 million for the full year, primarily due to stock compensation. Adjusted EBITDA was positive at $10.2 million for Q4 and $52.7 million for the full year. For 2023, LifeStance anticipates revenue between $980 million and $1.02 billion and a Center Margin of $270 to $290 million. The outlook emphasizes a focus on streamlining operations for sustainable growth.
LifeStance Health Group, Inc. (NASDAQ: LFST) will announce its fourth quarter earnings on March 8, 2023, before the market opens. A live earnings conference call will take place at 8:30 a.m. Eastern time on the same day, accessible domestically at 1-800-715-9871 or internationally at 1-646-307-1963, using conference ID 4226236. The call will be available for replay on their Investor Relations website. LifeStance, founded in 2017, is a leading provider of outpatient mental health care, offering services through approximately 600 centers in 32 states, employing around 5,400 mental health professionals.
LifeStance Health (NASDAQ: LFST), a leading provider of outpatient mental health care, has been Certified™ by Great Place to Work® for the second consecutive year. This recognition highlights the company's commitment to enhancing employee experience and workplace culture, as validated by feedback from its staff. Research indicates that employees at Certified workplaces report significantly higher job satisfaction and a fair compensation structure. LifeStance emphasizes mental wellness, financial wellness, and community engagement as key components of its corporate culture.
LifeStance Health Group (NASDAQ: LFST) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, in San Francisco. The presentation will feature CEO Ken Burdick and President Danish Qureshi, starting at 7:30 a.m. Pacific time, and will be moderated by Lisa Gill. The event will be webcast live, with a replay available afterward on the company's Investor Relations website. LifeStance, founded in 2017, is a major provider of outpatient mental health care across the U.S., employing approximately 5,400 mental health professionals.
LifeStance Health Group (NASDAQ: LFST) reported Q3 2022 revenue of $217.6 million, a 25% increase from Q3 2021. The company achieved a net loss of $37.9 million, significantly improved from $120.5 million a year prior, mainly due to $34.9 million in stock-based compensation. Adjusted EBITDA rose 44% to $15.4 million. Despite expanding its clinician base by 24% to 5,431, the company adjusted its 2022 revenue guidance to $845-$850 million, citing lower visit volumes and increased costs. LifeStance continues to focus on growth and operational improvements.
LifeStance Health (NASDAQ: LFST) announces J. Michael Bruff's transition to Business Transformation Officer, effective November 10, 2022, with David Bourdon succeeding him as Chief Financial Officer. This leadership shift aims to strengthen the company's focus on strategic initiatives to enhance operational efficiency and patient experience. Bourdon brings over 20 years of relevant experience from Magellan Health and Cigna, aligning with LifeStance's goals for growth and profitability in mental healthcare services.
LifeStance Health Group, Inc. (NASDAQ: LFST) is set to release its third quarter earnings on November 8, 2022, after market close. A live conference call will follow at 4:30 p.m. ET to discuss the results. Interested participants can join via a dedicated phone line or listen to the live audio webcast available on the LifeStance Investor Relations website. Founded in 2017, LifeStance is a leading provider of outpatient mental health care, employing around 5,200 mental health professionals across 32 states and approximately 600 centers.
Lowey Dannenberg is investigating potential violations of consumer protection laws by LifeStance Health Group, Inc. (NASDAQ:LFST). The investigation focuses on whether LifeStance engaged in unlawful practices related to its marketing of psychiatric services. Consumers who believe they have suffered losses are encouraged to contact the firm for more information.
Lowey Dannenberg has a strong background in supporting institutional and individual investors who have experienced financial losses due to corporate fraud, with a history of recovering billions for clients.
Lowey Dannenberg is investigating LifeStance Health Group (NASDAQ:LFST) for potential violations of consumer protection laws regarding its psychiatric services marketing practices. This investigation seeks to determine if LifeStance's actions have led to consumer harm or violated legal standards. Affected consumers are encouraged to reach out to the firm for further discussion and possible participation in the investigation.
LifeStance Health (NASDAQ: LFST) appointed Ken Burdick as CEO and Chairman, effective September 7, 2022, succeeding retiring founder Michael Lester, who will remain a Strategic Advisor. Burdick’s extensive 40-year healthcare experience includes leadership roles at Centene and WellCare. The transition aims to drive growth and enhance care access, supported by Danish Qureshi, now President and COO. LifeStance operates over 600 centers nationwide, employing around 5,200 clinicians, and emphasizes affordable, quality mental healthcare.
FAQ
What is the current stock price of Lifestance Health Group (LFST)?
What is the market cap of Lifestance Health Group (LFST)?
